Stocks and Investing Stocks and Investing
Mon, February 20, 2023
Fri, February 17, 2023

Vikram Purohit Maintained (ASND) at Buy with Increased Target to $151 on, Feb 17th, 2023


Published on 2024-10-28 01:44:45 - WOPRAI, Vikram Purohit
  Print publication without navigation


Vikram Purohit of Morgan Stanley, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $148 to $151 on, Feb 17th, 2023.

Vikram has made no other calls on ASND in the last 4 months.



There are 5 other peers that have a rating on ASND. Out of the 5 peers that are also analyzing ASND, 0 agree with Vikram's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Vikram


  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $163 on, Tuesday, January 17th, 2023
  • Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $177 on, Tuesday, January 3rd, 2023
  • Andreas Argyrides of "Wedbush" Maintained at Buy with Increased Target to $164 on, Monday, November 14th, 2022
  • David Lebowitz of "Citigroup" Maintained at Strong Buy with Increased Target to $163 on, Thursday, November 3rd, 2022
  • Paul Choi of "Goldman Sachs" Initiated at Strong Buy and Held Target at $174 on, Thursday, October 20th, 2022
Contributing Sources